On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevax, Moderna’s COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.

The company said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its COVID-19 shot, including one for viral infection shingles. The company also announced a partnership with Adium Pharma for the distribution of its vaccine in Latin America.